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Review Article
Bacillus Calmette–Guérin and Bladder Cancer
Azad H.A. Razack, Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Bladder cancer is the second most common cancer of the urinary tract, and overall it is among the top 
10 cancers in men. Transitional cell carcinoma (TCC) is the most common type, with the majority being
superficial disease, i.e. the tumour has not gone beyond the lamina propria. The main problem with
superficial TCC is the high recurrence rate. Various forms of treatment methods have been attempted to
reduce the recurrence rate, with intravesical bacillus Calmette–Guérin (BCG) being the most successful
to date. In fact, intravesical BCG is one of the most successful forms of immunotherapy in the treatment
of any form of cancer. This article is a general review of BCG in bladder cancer with an emphasis on the
indication and mechanism of action in reducing recurrence and progression. [Asian J Surg 2007;30(4):302–9]
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Introduction
Bladder cancer is the seventh most common cancer among
men worldwide. The incidence is much lower in females,
with a male to female ratio of 4:1. It is more common in
the developed world compared to the developing coun-
tries.1 In South East Asia, the incidence in 2002 was 2.7 per
100,000 in males and 0.8 per 100,000 in females, making
it the ninth most common cancer in men.1 In Europe, blad-
der cancer accounts for 5–10% of all malignancies among
males.1 In the United States, the estimated number of new
cases in 2003 was 57,400, and the estimated number of
deaths was 12,500.2 In the United Kingdom, the number
of new cases reported in 2000 was 11,081, and the number
of deaths in 2002 was 4,908.3
Most bladder cancers are transitional cell carcinoma
(TCC), accounting for about 93% of cases. The rest include
squamous cell carcinoma and adenocarcinoma.4 About
70% of bladder tumours are classified as “superficial”,
that is, the tumour has not gone beyond the lamina propria
on presentation, while the rest are invasive. Among the
superficial tumours, 70% are Ta while 20% are T1, with
carcinoma in situ (CIS) comprising the remaining 10%.
The TNM staging is as shown in Table 1.5
Diagnosis and treatment
Haematuria is the most common presenting symptom in
patients diagnosed with bladder cancer. These patients
are investigated by intravenous urography or ultrasound,
urine cytology and flexible cystoscopy. If cystoscopy con-
firms the presence of a bladder tumour, these patients
will subsequently undergo transurethral resection of blad-
der tumour (TURBT) for histological confirmation and
staging. Further treatment depends on the histological
stage and grade. Those with invasive tumour, i.e. T2 or T3,
will undergo radical treatment, with radical cystectomy
and urinary diversion being the most common procedure.
Patients who are not suitable for surgery can undergo
radiotherapy. However, a combination of chemotherapy
and radiotherapy has recently been attempted to preserve
the bladder.6
The majority of patients will have a Ta or T1 tumour.
As shown in Table 2, they can be classified as low risk,
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intermediate risk or high risk to guide subsequent treat-
ment. The main problem with these patients is recurrence
in the majority of patients, and progression.7
Recurrence and progression
The recurrence rate for low risk patients is around 15%
and 31% at 1 and 5 years, respectively, while for high risk
patients it is 61% and 78% at 1 and 5 years, respectively.
This is based on the extensive review carried out by Sylvester
et al of 2,596 patients from seven European Organisation
for Research and Treatment of Cancer (EORTC) trials.8
The same review also showed that in low risk patients, the
progression rate was 0.2% and 0.8% at 1 and 5 years,
respectively, while in high risk patients it was 17% and
45% at 1 and 5 years, respectively.8
Table 1. TNM classification of bladder tumours
Tumour type Description
Primary tumour (T)
Tx Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ, flat tumour
Ta Noninvasive primary tumour
T1 Tumour invades subepithelial connective tissue
T2 Tumour invades muscle
T2a Tumour invades superficial muscle
T2b Tumour invades deep muscle
T3 Tumour invades perivesical fat
T3a Microscopically
T3b Macroscopically
T4 Tumour invades any of the following: prostate, uterus, vagina, pelvic wall or 
abdominal wall
T4a Tumour invades prostate, uterus or vagina
T4b Tumour invades pelvic wall or abdominal wall
Regional lymph nodes (N)
Nx Regional nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single lymph node measuring ≤ 2 cm in greatest dimension
N2 Metastasis in a single lymph node measuring > 2 cm but not > 5 cm in greatest 
dimension or multiple lymph nodes, none measuring > 5 cm in greatest dimension
N3 Metastasis in a lymph node measuring > 5 cm in greatest dimension
Distant metastasis (M)
Mx Distant metastasis cannot be assessed
M1 No distant metastasis
M2 Distant metastasis
Table 2. Patient risk classification
Risk status Description
Low Single, Ta, G1, < 3 cm in diameter
High T1, G3, multifocal or highly recurrent CIS
Intermediate All other tumours, Ta, Ta-1, G1-2, multifocal, > 3 cm in diameter
G = grade of tumour and refers to the differentiation of the tumour; G1 = tumours that have least degree of anaplasia compatible with 
the diagnosis of malignancy, i.e. well differentiated; G3 = tumours with the most severe degree of anaplasia, i.e. poorly differentiated; 
G2 = tumours in between; CIS = carcinoma in situ.
The most important factors for progression are T cat-
egory, grade and presence of CIS. To better improve the
prognosis of T1 disease, some have suggested the subclas-
sification of T1 into T1a and T1b. T1a is where the lesion
has gone into the lamina propria but has not involved the
muscularis mucosae, while T1b is where there is involve-
ment of the muscularis mucosae. Hasui et al have shown
that the progression rate of T1b is significantly higher
than T1a irrespective of the grade, size and number of
tumours.9
As far as the grading is concerned, various grading 
systems have been used, but the one most widely used cur-
rently is the original Mostofi grading, which was subse-
quently adopted by the World Health Organisation (WHO)
in 1973. In this system, there are three grades based on the
differentiation of the tumour, as described in Table 2. The
main criticism regarding this system is that the criteria
used to assign a grade are vague and subjective, resulting in
poor interobserver reproducibility. Further, the classifica-
tion of grade 2 was broad and not very specific.10 In view
of this, in 1998, the WHO and the International Society
of Urologic Pathologists put forward a consensus classifi-
cation of urothelial neoplasms that has now been adopted
as the 2004 WHO grading system. The classification is
shown in Table 3. In this system, each grade has a more
detailed histological description that should help prevent
the interobserver variation noted in the WHO 1973 grad-
ing system. As far as prognosis is concerned, there seems
to be better correlation with the new system, although the
system has been slow to gain acceptability by urologists
and pathologists, as most recent publications continue to
use the 1973 grading system.11,12 In view of this, there has
been a recommendation made to use both classifications
together in the interim period to increase familiarization
with the new grading system. Table 4 shows the correlation
between the two systems.10,12
Another important risk factor is tumour recurrence at
the first surveillance cystoscopy 3 months after the pri-
mary resection. Many have suggested a repeat TURBT
between 2 and 6 weeks after the first resection to ensure
that the recurrence is not due to residual tumour. It was
shown in a study by Herr that, in a repeat resection done
2–6 weeks after the initial resection, 76% of the patients had
residual disease and 29% had a higher stage including inva-
sive disease.13 The presence of residual tumour and higher
stage tumour during re-resection increases in T1, higher
grade, multiple and solid tumours.14 Thus, second-look
transurethral resection (TUR) is currently recommended for
patients with T1, high grade, multiple tumours and those
for whom complete primary resection was not possible
for various reasons.
In an attempt to reduce recurrence and progression,
many different types of treatment have been attempted,
but the most successful is intravesical treatment. This
form of treatment involves instillation of different agents
directly into the bladder via a urethral catheter. Many
agents have been used, among them thiotepa, adriamycin,
mitomycin C, epirubicin and bacillus Calmette–Guérin
(BCG).15 Intravesical BCG treatment of bladder cancer
has been the most successful immunotherapy of any cancer.
Development of BCG
Nocard isolated Mycobacterium bovis from a cow with
tuberculous mastitis in 1904. In 1908, Calmette and Guérin,
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Table 3. 2004 World Health Organisation classification of
urothelial neoplasm
Hyperplasia
Flat hyperplasia
Papillary hyperplasia
Flat lesions with atypia
Reactive (inflammatory) atypia
Dysplasia
Carcinoma in situ*
Papillary neoplasms
Papilloma
Papillary neoplasm of low malignant potential (PUNLMP)
Papillary carcinoma, low grade
Papillary carcinoma, high grade
*May include cases formerly classified as severe dysplasia.
Table 4. Relation of World Health Organisation (WHO) 1973 to
WHO 2004
WHO 1973 WHO 2004
Papilloma Papilloma
Grade 1 PUNLMP
Grade 2 Low grade
Grade 3 High grade
PUNLMP = papillary neoplasm of low malignant potential.






while working on an antituberculosis vaccine, noted that
the culture gradually lost its virulence with each passage.
After 231 passages over a period of 13 years, it became
avirulent. This special M. bovis strain was named Bacillus
of Calmette and Guérin, or BCG.16 Storage was a problem
at that time so it was necessary to subculture, which led
to genetic variability and the emergence of various sub-
strains. The most widely used substrains are Connaught,
Pasteur, Tice and Tokyo.17
In 1929, Pearl observed that patients who suffered from
tuberculosis had lower frequency of cancer, and BCG as 
a cancer therapy was first suggested, but it was only in the
1960s that it was taken up.18 Mathe et al in 1969 showed
promising results in treating lymphoblastic leukaemia
with BCG.19 However, no further progress was made due to
the inability to reproduce the results of the early studies as
well as the development of successful modern chemother-
apy and radiotherapy.20
In 1974, Zbar and Rapp21 formulated conditions nec-
essary for antitumour effect with BCG:
• ability to develop an immune response to mycobac-
teria antigens;
• adequate number of living bacilli;
• close contact between BCG and tumour cells;
• the tumour burden must be small.
In 1976, Morales et al noted that all the conditions
were present in superficial bladder cancer and was able to
show a decrease in recurrence rate in the nine patients he
initially treated.22 After Lamm et al confirmed these find-
ings in a larger study, BCG has been widely used in the
treatment of superficial bladder cancer.23
Intravesical BCG treatment
Intravesical BCG has been used in TCC of the bladder for
three main indications. It is most commonly used as 
a prophylaxis in superficial bladder cancer after initial
TURBT to reduce recurrence and progression. It is also
used in the treatment of CIS. The other indication is in
the eradication of residual tumour not completely cleared
during TURBT for various reasons.
The most common treatment regimen today is the
one originally introduced by Morales et al but without 
the simultaneous intradermal BCG. The early practice of
using intradermal BCG to enhance the immune response
to intravesical BCG has been subsequently shown to be of
no benefit.24 The freeze-dried BCG powder is mixed with
50 mL of saline and instilled into the bladder via a urethral
catheter. The patient retains the fluid in the bladder for
around 1–2 hours. The treatment consists of once weekly
instillation of BCG for 6 weeks. The best method of meas-
uring the strength of the various strains of BCG used is by
the number of colony forming units (CFU). This is because
the efficacy of the BCG depends on the number of viable
bacteria in the instillation used. Kelley et al measured the
CFU in each batch of BCG vials and noted that the batch
with 6 × 106 CFU had a higher recurrence rate compared
to another batch with 300 billion CFU.25
Prophylactic treatment
One of the main aims of treating patients with intravesi-
cal BCG is to reduce the recurrence and progression rate.
Many studies have shown a response rate varying from
40% to 60%. The response also depends on the stage and
grade of tumour. The risk groups for superficial TCC of
the bladder is as shown in Table 2 based on European
Association of Urology guidelines.26 In one of the early
randomized trials, Lamm noted a 52% recurrence rate in
the control group compared with a 20% recurrence rate in
the BCG group.27 The recurrence-free interval in the treat-
ment group and control group was 48 months and 24
months, respectively. One of the best results has been
from Offenburg, in Germany, where 109 of the 126 patients
who were only started on intravesical BCG after repeated
resections were found to be tumour-free. After a median
follow-up of 4 years, 71% of the patients remained tumour-
free after one cycle. This increased to 86% after a second
cycle for the initial failures.28 The reason for the high suc-
cess rate is most probably due to the low tumour burden
before BCG treatment was commenced. A meta-analysis
carried out by Sylvester et al for the EORTC showed a rel-
ative reduction in risk of progression of 32% and 35% for
patients with papillary tumour and CIS, respectively.29
The decrease in progression rate has been noted to have
an impact on the mortality rate. Herr et al noted an
improved 5-year survival rate of 87% in the BCG group
compared to 63% in the TUR only group.30 They also
showed that cancer deaths were reduced from 37% to 12%.
In a Cochrane review, it was noted that in medium-risk
and high-risk groups, BCG reduced the risk of recurrence
by 54% compared to TUR alone.31
BCG has been very successful in the treatment of
T1G3 tumours, which has a recurrence and progression
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rate of > 80% and 50% respectively.32 Many urologists have
suggested radical cystectomy as the treatment of choice.
However, BCG has made a great impact in the manage-
ment of these patients. Currently, most urologists would
attempt BCG as their first line of treatment and would
only consider radical cystectomy after failure of one or two
cycles of treatment. Peyromaure et al showed that patients
with a T1G3 tumour treated with BCG had a recurrence
rate and progression rate of 42.1% and 22.8%, respectively,
after a median follow-up of 53 months.33 In another study,
Brake at al reported 27% recurrence and 16% progression
after one or two cycles. Overall, 82% of the patients
remained tumour-free after a mean follow-up of 3 years.34
CIS
CIS in the bladder is a high-grade noninvasive disease
with a progression rate of more than 50%. The complete
response rate to intravesical BCG varies between 60% and
79% based on 41 studies with a total of 1,496 patients.35
Lamm et al showed a complete response rate of 70% with
a median duration of response of 39 months when BCG was
used in the treatment of CIS; 45% of patients were disease-
free after 5 years and 64% of patients who had a complete
response remained disease-free for 5 years or more.36
In another South West Oncology Group (SWOG) study,
an additional 3-week course of BCG at 3 months resulted
in a further 25% increase in the complete response rate at
6 months, and with further maintenance every 6 months
for 3 years, there was an estimated 5-year disease-free rate
of more than 75%.36 With these impressive results, BCG
has replaced radical cystectomy as the treatment of choice
in the management of patients with CIS.
Residual disease
Eradication of residual disease is another indication for
using intravesical BCG. This group of patients form a very
small proportion of patients who have BCG treatment
and are usually patients who are not fit to undergo endo-
scopic resection or patients with very extensive Ta or T1
disease. The response rate is usually around 60% to 70%.37
BCG vs. intravesical chemotherapy
BCG has been shown to be superior to many of the intraves-
ical chemotherapy agents used. However, very few studies
have shown it to be better than mitomycin C (MMC) in
terms of recurrence. One of the main reasons for this is
that in many of the studies, patients of varying risk groups
were analysed together. In the Cochrane review, when BCG
was compared to mitomycin C, it was noted that tumour
recurrence was significantly reduced with BCG only in the
subgroup of patients at high risk of tumour recurrence.
However, there was no difference in terms of disease pro-
gression or survival.38 However, others have shown a sur-
vival benefit with BCG treatment. Herr et al in their review
reported that in high risk and recurrent superficial bladder
cancer, patients treated with intravesical BCG had superior
disease-free survival.39 Lamm et al also showed that main-
tenance BCG improved disease-free survival.40
Dosage and schedule
The optimal dose and schedule of BCG has not yet been
clearly defined. As noted above, a second cycle of BCG has
been found to be beneficial with a further improvement
in tumour-free rate of 20–30%.41,42 However, the risk of
progression and metastases outweighs the benefit of more
than two courses of BCG. The risk of muscle invasive
tumour was 30% and the risk of metastases was 50% in 
a study by Catalona et al in patients receiving more than
two courses of BCG.43
Low-dose BCG has been shown to be as effective as
full-dose BCG in a number of studies. The doses used var-
ied from half to quarter strength. It has been shown that
low-dose BCG can reduce the side effects without compro-
mising efficacy.44,45 Further large-scale studies are required
before the optimum dose can be defined.
Side effects are the main reason for discontinuing the
treatment in many studies and are especially important
in maintenance treatment as discussed below.
Maintenance
The role of maintenance therapy after the induction course
of BCG is controversial. Maintenance therapy involves
continuous treatment with BCG after successful induction
therapy. It consists of shorter cycles given periodically.
The EORTC meta-analysis showed that the trials result-
ing in a reduction in risk of progression were those with
maintenance therapy.29 However, there is no standard main-
tenance therapy schedule, but the one with the best reported
results is that by SWOG from USA. In their schedule, the
maintenance therapy consisted of 3-weekly instillations
at 3, 6, 9, 12, 18, 24, 30 and 36 weeks.40 The main concern
regarding maintenance therapy has been the side effects
associated with BCG. In the SWOG study, only 16% of
patients completed the full course of maintenance mainly
due to side effects.40 However, the EORTC study found that
patient drop-out due to side effects mainly occurred in the
first 6 months and the local side effects remained fairly
constant during the entire treatment period while the sys-
temic side effects were observed more frequently during
the first 6 months.46
Overall, it seems that maintenance therapy is benefi-
cial if the patient is able to tolerate the side effects. The
main side effects are cystitis, dysuria and frequency which
can occur in as high as 90% of the patients treated with
BCG. Other side effects include haematuria in a third and
fever in about 3%. The majority of patients tolerate the
treatment well and the side effects are usually self-limiting.
The most serious complication is BCG sepsis, which was
noted in less than 0.5% and occurs if given immediately
after tumour resection or at the time of severe cystitis. This
is most probably due to intravascular absorption through
an inflamed bladder wall.47
Mechanism of action
The exact antitumour mechanism of BCG is not clear but it
is known that a complex cascade of immunomodulating
processes is involved. The importance of an intact immune
system in the antitumour activity of BCG was first demon-
strated by Ratliff and colleagues.48 They noted that BCG
was not effective in eradicating the disease in athymic mice.
It was also shown that animals depleted of T cells were
not capable of mediating antitumour activity after BCG
treatment.49 This suggests that T lymphocytes and cell-
mediated immunity are important in the immune response
to BCG.
After intravesical instillation, live mycobacteria attach
to the urothelial lining. This binding is facilitated by
fibronectin, which is a component of the extracellular
matrix, and BCG undergoes endocytosis. The contact
between BCG and the epithelium is important as BCG-
induced antitumour activity is localized to the site of 
contact.49,50 This process leaves bacterial cell surface gly-
coprotein attached to the epithelial cell membrane and
this interaction of BCG leads to the activation of urothe-
lial and antigen presenting cells (APC). The APC include
macrophages, B lymphocytes, dendritic cells and Langer-
hans cells. The APC process and present antigens which
are then linked to major histocompatibility (MHC) class
II molecules for recognition by T helper cells.51
Intravesical BCG therapy has been noted to induce
local production of various cytokines including inter-
leukin-1 (IL-1), IL-2, IL-5, IL-6, IL-8, IL-10, IL-12, IL-18,
interferon gamma (IFN-γ) and tumour necrosis factor
alpha (TNF-α).52 Cytokines are soluble mediators secreted
by macrophages, monocytes or lymphocytes. They are
mediators of stimulatory or inhibitory signals between
cells.53 Their functions include attracting APC to the site
of infection and T cell differentiation and proliferation.
Many of these cytokines are known to be involved in the
initiation or maintenance of the inflammatory process.52
It is thought that the initial production of cytokines,
after BCG instillation, is by macrophages and urothelial
cells and further production is by activated T cells.51,52
The cytokines produced after intravesical BCG have been
identified in the urine of patients. The majority of the
cytokines produced are mainly the T helper type 1 (TH1)
cytokines like IFN-γ, IL-2 and IL-12. It has also been
shown that the production of cytokines associated with
TH2, like IL-4, are decreased and patients who have a high
level of TH2-associated cytokines are more likely to have
BCG failure.54,55 A few studies have shown that cytokine
levels can be used to predict the long-term response to
BCG treatment with higher levels indicating a lower
recurrence rate and a longer recurrence-free interval.56–58
The main mechanism by which BCG stimulates the
immune system to overcome the tumour is by playing 
a role, either directly or indirectly, in the production of
effector cells. These include the stimulation of cytotoxic
T lymphocytes (CTL), natural killer (NK) cells, lymphokine-
activated killer (LAK) cells and BCG-activated killer cells
(BAK). BAK cells are similar to NK and LAK cells but have
some differences, as the effects are believed to last longer
than those of the other killer cells.51,52,59 The production
of effector cells is stimulated by cytokines. The cytokines,
especially IFN-γ, also induce the expression and upregula-
tion of MHC class II and intracellular adhesion molecular
1 by the tumour cells. This helps in the recognition and
destruction of the tumour by the effector cells.50
The peak immune response is usually noted around
6–24 hours after instillation and there is a cumulative
increase in response up to the fifth or sixth cycle. The re-
sponse slowly continues to wane over a period but the exact
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duration of response is not clear as cytokine-producing
infiltrates have been identified up to 21 months after
treatment.60 This is the rationale for maintenance therapy.
Conclusion
Intravesical BCG is an effective and well established
immunotherapy for superficial TCC of the bladder.
However, the optimum dose and schedule of treatment is
yet to be defined. The other important aspect that needs
to be established is the prognostic or predictive factors of
treatment response. This is important for selecting patients
who will benefit from the treatment to avoid unnecessary
radical treatment and at the same time identify non-
responders early on so that they can be offered alternative
treatment without compromising their prognosis.
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